Orchestra BioMed Holdings (OBIO) Enterprise Value (2020 - 2026)

Orchestra BioMed Holdings (OBIO) has reported Enterprise Value for 7 consecutive years, with -$84.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Enterprise Value fell 69.65% year-over-year to -$84.6 million; the TTM figure through Mar 2026 stood at -$84.6 million (down 69.65% YoY), while the FY2025 annual figure was -$146.6 million, down 44.67% from the prior year.
• Enterprise Value improved to -$84.6 million in Q1 2026 per OBIO's latest filing, from -$146.6 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$735217.0 in Q3 2022 and bottomed at -$215.9 million in Q2 2023.
• Historically, Enterprise Value has averaged -$73.4 million across 5 years, with a median of -$84.6 million in 2026.
• Annual changes were most pronounced in 2023 — Enterprise Value plunged 16418.84% — and 2024, when it surged 81.64%.
• Orchestra BioMed Holdings' Enterprise Value stood at -$19.9 million in 2022, then slumped by 340.5% to -$87.5 million in 2023, then retreated by 15.79% to -$101.4 million in 2024, then sank by 44.67% to -$146.6 million in 2025, then soared by 42.28% to -$84.6 million in 2026.
• Business Quant data shows OBIO's Enterprise Value at -$84.6 million in Q1 2026, -$146.6 million in Q4 2025, and -$95.8 million in Q3 2025.